Gilead announced a second positive Phase III trial showing its two‑drug regimen achieved non‑inferiority versus the established triple therapy Biktarvy. The result advances Gilead’s bid to offer an alternative HIV treatment cocktail and supports plans for regulatory submissions in major markets. The data add to a growing body of evidence supporting simplified regimens that maintain viral suppression while reducing pill burden or target-specific safety profiles. Non‑inferiority against a widely used standard like Biktarvy will be central to label discussions and formulary placement. Regulatory reviews will examine durability of suppression, resistance profiles, and real-world adherence implications. If approved, the regimen could shift prescribing patterns and competition among single- and dual‑tablet HIV therapies.